Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema.
Emphysema is characterized by the destruction of alveoli and alveolar ducts within the lungs. Retinoid signaling is believed to play a role in alveologenesis, with the retinoic acid receptor gamma thought to be required for alveolar formation. Based on this hypothesis, Roche Holding AG is developing palovarotene (R-667, RO-3300074), a selective retinoic acid receptor gamma agonist for the treatment of emphysema. In small animal studies, palovarotene was claimed to reverse the structural, functional and inflammatory features of cigarette smoke-induced emphysema. Phase I clinical trials of palovarotene in patients with emphysema demonstrated that the drug is well tolerated, with improvements observed in markers of emphysema progression. Unlike all-trans retinoic acid, the pharmacokinetic profile of palovarotene appears to be dose-proportional. At the time of publication, a phase II, placebo-controlled trial was ongoing, and was expected to report prospective measurements of exercise, gas transfer and lung densitometry endpoints. The development of a selective retinoic acid receptor gamma agonist for the treatment of emphysema represents the first of a new class of small-molecule regenerative therapies that may prove useful for the treatment of destructive or age-related lung disease.
Hind
Matthew
M
Royal Brompton Hospital, Biomedical Research Unit, Department of Respiratory Medicine, and National Heart and Lung Institute, Imperial College, Fulham Road, London, SW3 6NP, UK. m.hind@imperial.ac.uk
Stinchcombe
Sian
S
D000818:Animals; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004646:Emphysema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D011650:Pulmonary Alveoli / Q000473:pathology; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D018168:Receptors, Retinoic Acid / Q000819:agonists*; D015398:Signal Transduction; D012907:Smoking / Q000009:adverse effects; D013267:Stilbenes / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000097768:Retinoic Acid Receptor gamma
D011720:Pyrazoles; D018168:Receptors, Retinoic Acid; D013267:Stilbenes; D000097768:Retinoic Acid Receptor gamma; C546535:Palovarotene